The so-called oral hypoglycemic drugs mainly refer to western drugs. At present, the oral hypoglycemic drugs commonly used in clinical practice include sulfonylureas, biguanides and bypyridamides. The main role of sulfonylurea hypoglycemic drugs is to stimulate insulin secretion, the hypoglycemic effect is moderately strong, there are D860 (methanesulfonylurea), eugenol, mepiquat, glycomet, Damacan, among which eugenol has the strongest effect, mepiquat has a fast and short effect, Damacan has a longer effect, glycomet can be used for patients with diabetic nephropathy. The main role of biguanide hypoglycemic drugs is to reduce appetite, reduce the absorption of sugar, and at the same time can increase the sensitivity of insulin, including hypoglycemia, metformin. Among them, glucagon has been nearly eliminated. The third category of oral medication is Bystolic, which mainly inhibits the breakdown of sugar and reduces postprandial glucose by relieving the absorption of glucose. Secondly, there are three new drugs under development in foreign countries, some of which have already entered the clinical trial stage, for example, GLP-1 has been marketed.